The Japan Ministry of Health, Labour and Welfare (MHLW) has granted manufacturing and marketing approval to Takeda’s Covid-19 vaccine, Nuvaxovid Intramuscular Injection, for initial and booster vaccination in people of the age 18 years and above. 

The recombinant protein-based Covid-19 vaccine contains Matrix-M adjuvant.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It can be stored at a refrigerated temperature of 2℃ to 8℃ and requires a standard vaccine supply chain for transportation.

In August 2020, Takeda and Novavax entered a collaboration to develop, manufacture and supply the latter’s Covid‑19 vaccine candidate in Japan. 

Under the deal, Novavax licensed and transferred its manufacturing technologies that enabled Takeda in the development and production of the vaccine at its facility in Hikari, Japan. 

Through the MHLW and Japan Agency for Medical Research and Development, Takeda obtained funds for the technology transfer as well as research and development to produce the vaccine at the Hikari site. 

With the latest approval, Takeda will commence supply of the vaccine doses procured by the Government of Japan in the coming days.  

The MHLW approval is based on the New Drug Application (NDA) submission made by Takeda which comprises positive interim data from a Phase I/II trial in Japan as well as various other studies in the UK, US, Mexico and Australia. 

Interim results from the Phase I/II trial were found to be in line with priorly reported trial data. 

Furthermore, no serious adverse events were noted in the trial and the vaccine was found to be well-tolerated. 

Additional safety and efficacy findings were presented to the regulatory agency to support booster vaccination, including from a Phase II trial carried out by Novavax in South Africa.

Takeda Global Vaccine Business Unit president Gary Dubin said: “Covid-19 continues to pose a significant threat to the health and well-being of our global community.

“We are proud to contribute to the development of Nuvaxovid and to manufacture the vaccine at our Hikari facilities, continuing our commitment to the Covid-19 public health response in Japan.”

In September last year, the MHLW agreed to purchase 150 million doses of the vaccine following approval.